Cognition Therapeutics Inc.
CogRx is a clinical-stage pharmaceutical company developing novel drugs that work through a completely new mechanism to treat or prevent Alzheimer's disease.
Cognition Therapeutics (CogRx) is a clinical-stage small molecule therapeutics company focused on the discovery and development of novel drugs for neurodegenerative diseases. CogRx has discovered first-in-class therapeutics that selectively block soluble Aβ oligomers from causing cognitive decline. CogRx’s compounds work through a new neuronal Aβ oligomer receptor complex to reverse memory loss in Alzheimer's disease models.